| 股票代码：600521 | 股票简称：华海药业 | 公告编号：临 | 2024-086 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | | 浙江华海药业股份有限公司 第八届监事会第十六次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第八届监事会第十六次临时会 议于二零二四年八月二十七日在公司四楼会议室以通讯方式召开。会议应到会监 事三人，实际到会监事三人，符合召开监事会会议的法定人数。会议由监事王虎 根先生主持。会议程序符合《中华人民共和国公司法》（以下简称"公司法"）、《中 华人民共和国证券法》（以下简称"《证券法》"）及《浙江华海药业股份有限公司 章程》（以下简称"公司章程"）的规定，会议合法有效。会议审议并一致通过了 如下议案： 一、审议通过了《关于募投项目结项并将节余募集资金用于新建项目和永久 补充流动资金的议案》 二、审议通过了《关于延长公司向特定对象发行 ...

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2024-085 号 浙江华海药业股份有限公司 第八届董事会第二十七次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第八届董事会第二十七次临时会 议于二零二四年八月二十七日上午九点在公司四楼会议室以通讯方式召开。会议应 到会董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司 董事长李宏先生主持。会议程序符合《中华人民共和国公司法》（以下简称"公司法"）、 《中华人民共和国证券法》（以下简称"《证券法》"）及《浙江华海药业股份有限公 司章程》（以下简称"公司章程"）的规定。会议审议并通过了如下决议： 一、审议通过了《关于募投项目结项并将节余募集资金用于新建项目和永久补 充流动资金的议案》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 具体内容详见公司于 2024 年 8 月 28 日刊登在中国证券报、上海证券报、证券 时报、证券日报及上 ...

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is expected to be between 728 million and 785 million CNY, representing an increase of approximately 159.18 million to 216.18 million CNY, or a year-on-year growth of about 28% to 38%[3]. - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 745 million and 810 million CNY, reflecting an increase of approximately 96.84 million to 161.84 million CNY, or a year-on-year growth of about 15% to 25%[3]. - The net profit for the same period last year was 568.82 million CNY, and the net profit after deducting non-recurring gains and losses was 648.16 million CNY[5]. Factors Contributing to Growth - The increase in net profit is attributed to the continuous introduction and gradual increase in sales of new products, effective market expansion, and improvements in sales team structure and global sales network[6]. - The company has enhanced its cost control capabilities and overall strength through lean management optimization and technological upgrades, contributing to significant revenue growth[6]. Earnings Forecast - The earnings forecast is based on preliminary estimates and has not been audited, with final figures to be disclosed in the official half-year report[7]. - There are no major uncertainties affecting the accuracy of this earnings forecast[7].

这个周末资本市场最热闹的事还是政府最新一轮针对房地产的救市，周五连续落地多个措施，助推国证地产上涨7.4%，万科保利双双涨停。其中比较重 要的有： 一天连发四道令箭，可见政府决心之坚决，援救房市刻不容缓。那么目前的房价到底怎么样了呢？统计局刚刚披露了4月份70个大中城市的房价指 数，其中二手房数据如下： | | 城市 | 环比 | 同比 | 1-4月平均 | | | 环比 | 同比 | 1-4月平均 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 上月=100 | 上年同月=100 | 上年同期=100 | | 城市 | 上月=100 | 上年同月=100 | 上年同期=100 | | 北 | 京 | 98.4 | 92.0 | 94.1 | 用 | m | 99.1 | 92.3 | 93.5 | | 天 | 津 | 98.7 | 95.0 | 96.5 | 奏皇岛 | | 99.0 | 93.0 | 94.2 | | 石家庄 | | 99.4 | 96.7 | 97.4 | 包 | ग्रें | 99.1 | 9 ...

Financial Performance - The company's operating revenue for Q1 2024 reached ¥2,498,671,124.15, representing a year-on-year increase of 21.36%[4] - Net profit attributable to shareholders was ¥270,842,789.22, reflecting a significant growth of 56.62% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥315,424,401.91, an increase of 67.29% year-on-year[4] - Basic and diluted earnings per share were both ¥0.19, up by 58.33% year-on-year[4] - Total operating revenue for Q1 2024 reached RMB 2,498,671,124.15, a 21.3% increase from RMB 2,058,913,113.43 in Q1 2023[16] - Net profit for Q1 2024 was RMB 273,944,434.55, representing a 62.7% increase compared to RMB 168,505,392.26 in Q1 2023[17] - The company reported a total profit of RMB 371,845,376.74 for Q1 2024, compared to RMB 240,883,645.68 in Q1 2023, marking a 54.4% increase[17] - The total comprehensive income for Q1 2024 was CNY 262,178,448.31, compared to CNY 148,538,126.97 in Q1 2023[25] Cash Flow - The net cash flow from operating activities was ¥853,246,043.03, showing a remarkable increase of 128.18% compared to the previous year[4] - Cash flow from operating activities generated RMB 853,246,043.03, significantly higher than RMB 373,933,429.54 in Q1 2023[19] - The net cash flow from investing activities was -471,690,659.45 RMB, a decrease from -521,104,230.29 RMB year-over-year[20] - The company reported a net cash flow from financing activities of 1,093,031,459.41 RMB, significantly higher than 548,627,492.74 RMB in the same quarter last year[20] - The net increase in cash and cash equivalents for the quarter was 1,485,562,536.52 RMB, compared to 367,599,362.76 RMB in the previous year[20] - The company's cash inflow from financing activities totaled 1,838,330,000.00 RMB, compared to 1,440,000,000.00 RMB in the previous year[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥20,089,317,179.86, an increase of 8.01% from the end of the previous year[4] - The company's total assets amounted to ¥20,089,317,179.86, compared to ¥18,599,969,612.84 at the end of 2023, reflecting a growth of approximately 8.0%[15] - Total current assets reached ¥8,901,797,081.57, up from ¥7,621,698,796.25, indicating an increase of about 16.8%[13] - The total liabilities increased to ¥11,599,242,747.86 from ¥10,348,854,672.57, which is an increase of approximately 12.1%[15] - The total liabilities increased to 8,776,729,779.72 RMB from 7,713,638,601.41 RMB year-over-year[22] - The company's equity attributable to shareholders rose to ¥8,319,436,460.31 from ¥8,076,851,901.19, showing an increase of about 3.0%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 72,310, with the top ten shareholders holding significant stakes[8] - The company has not reported any new strategies or significant changes in shareholder structure during the reporting period[12] Expenses - Total operating costs increased to RMB 2,099,036,620.37, up 17.1% from RMB 1,791,603,923.39 in the same period last year[16] - Research and development expenses for Q1 2024 were RMB 213,856,487.20, slightly up from RMB 202,193,404.97 in Q1 2023[16] - Sales expenses increased to RMB 490,541,619.20, a rise of 42.4% from RMB 344,775,680.27 in the previous year[16] - The company reported a financial expense of CNY 20,187,931.25 in Q1 2024, significantly reduced from CNY 68,797,147.86 in Q1 2023[24] Inventory and Investments - The company reported a total inventory of ¥3,236,962,151.59, down from ¥3,432,132,350.93, indicating a decrease of approximately 5.7%[13] - The company's inventory decreased to 2,330,768,586.18 RMB from 2,477,827,713.94 RMB year-over-year[21] - Long-term equity investments slightly decreased to ¥410,319,572.86 from ¥417,871,184.53, reflecting a decline of about 1.3%[14] - Long-term equity investments increased to 6,737,584,700.08 RMB from 6,586,268,218.76 RMB year-over-year[21] Market and Strategy - The sales team restructuring and market expansion efforts have led to improved market penetration and customer retention, contributing to revenue growth[7] - There were no new products or technologies announced in the current quarter[12]

Financial Performance - The company achieved operating revenue of CNY 8,308,719,758.46 in 2023, a year-on-year increase of 0.52%[19]. - The net profit attributable to shareholders was CNY 830,466,003.18, representing a decline of 28.88% compared to the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 888,522,218.59, down 25.96% year-on-year[19]. - The net cash flow from operating activities increased by 78.40% to CNY 2,217,021,274.88[19]. - The company's total assets at the end of 2023 were CNY 18,599,969,612.84, a 2.47% increase from the previous year[19]. - Basic earnings per share decreased by 29.63% to CNY 0.57 in 2023[20]. - The weighted average return on net assets was 10.64%, down 5.91 percentage points from the previous year[20]. - The company reported a total of CNY 2,101,155,202.27 in operating revenue for Q4 2023[22]. - The total revenue for the company reached CNY 8,249,178,955.91, with a year-on-year increase of 0.81%[63]. - The gross profit margin decreased by 1.99 percentage points compared to the previous year, primarily due to the impact of domestic procurement policies leading to lower prices[63]. - Revenue from finished drug sales amounted to CNY 4,931,569,375.42, reflecting a year-on-year increase of 4.46%[63]. - The revenue from technical services surged by 264.60% year-on-year, totaling CNY 122,163,764.93[63]. - Domestic revenue was CNY 4,036,320,572.33, showing a decline of 4.45% year-on-year[63]. - International revenue reached CNY 4,212,858,383.58, with a year-on-year increase of 6.42%[63]. Research and Development - The company is focusing on upgrading its R&D strategy and expanding its product categories to enhance market competitiveness[26]. - R&D investment accounted for 14.08% of revenue, with 15 new domestic formulation approvals and 20+ ongoing projects in biopharmaceuticals[30]. - The company has 20+ ongoing biopharmaceutical projects, with 11 entering clinical research stages, focusing on unmet clinical needs[30]. - The company is focusing on the development of innovative drugs in the fields of autoimmune diseases and oncology, with over 40 domestic and international invention patents applied and more than 20 projects currently under research[39]. - The company has a robust pipeline with several drugs at different stages of development, indicating a strong commitment to research and development[103]. - The company reported a total investment loss of 78,119,814.57 RMB for the period, with a fair value change loss of 46,198,316.37 RMB from its investment in Junshi Bioscience (688180) and 19,356,244.33 RMB from its investment in Amgen Pharmaceuticals (688373)[116]. - The company is actively involved in the research and development of pharmaceutical products, including the production of various monoclonal antibodies[123]. - The company has received FDA orphan drug designation for HB0034, indicating its potential significance in treating rare diseases[92]. Market Expansion and Strategy - The company is actively expanding its sales network in Belt and Road countries, aiming to capture more commercial opportunities[28]. - The company is committed to building a core competitive product pipeline by increasing the development of generic and first-generic drugs[130]. - The company aims to achieve sustainable growth by balancing internal growth and external expansion, enhancing its brand reputation and industry influence[128]. - The company plans to strengthen its innovation technology system and accelerate the pace of new product development, focusing on key research areas and aligning with international advanced levels[129]. - The company is focusing on enhancing its market presence through strategic expansions and product diversification[84]. - The company aims to enhance its global marketing system and create a strategic operational ecosystem focused on expanding its market share in both domestic and international markets[130]. Corporate Governance - The company has established a robust internal control management system in compliance with relevant laws and regulations[187]. - The company held three shareholder meetings during the reporting period, ensuring broad participation and adherence to legal requirements[148]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with relevant laws and regulations[148]. - The company has implemented strict insider information management to protect shareholder rights[149]. - The company has conducted training for employees to enhance awareness of insider information confidentiality[149]. - The company has established a scientific performance evaluation system linked to employee compensation and promotions, enhancing talent retention and governance[148]. Environmental and Safety Compliance - The company has increased its investment in safety and environmental protection facilities to enhance compliance and risk prevention capabilities[142]. - The company has implemented a comprehensive environmental protection mechanism as a key pollutant discharge unit[190]. - The company achieved a total COD discharge limit of 8.194 tons and ammonia nitrogen of 0.41 tons, meeting regulatory standards in 2023[190]. - The company operates a total of 1 wastewater discharge outlet located in the northern area of the plant, along with 12 gas discharge outlets, of which 2 are under construction[194]. - The total nitrogen oxides emissions for Zhejiang Huahai Pharmaceutical Co., Ltd. are capped at 6.465 tons for 2023, with actual emissions within the permitted range[194]. Talent and Workforce - The company has a strong talent pool, including over 100 high-level talents with overseas backgrounds, supporting its R&D capabilities[57]. - The number of R&D personnel is 1,848, accounting for 22.48% of the total workforce[73]. - The company has 113 employees with a doctoral degree and 707 with a master's degree, indicating a strong educational background among its workforce[176]. - The company has established a comprehensive talent training mechanism to support its rapid development and enhance its competitive strength[33]. Shareholder Returns - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on the total share capital after deducting shares held in the repurchase account[4]. - The total cash dividend amount for 2022 was approximately 354.54 million CNY, representing 42.69% of the net profit attributable to ordinary shareholders[182]. - The company’s cash dividend for 2022 was 0.24 CNY per share, which was implemented on July 3, 2023[179]. - The company plans to distribute a cash dividend of 0.2 CNY per share for the 2023 fiscal year, pending shareholder approval[179].

Financial Performance Expectations - Zhejiang Huahai Pharmaceutical Co., Ltd. expects Q1 2024 net profit attributable to shareholders to be between CNY 259.5 million and CNY 285.5 million, an increase of approximately CNY 86.57 million to CNY 112.57 million, representing a year-on-year growth of about 50% to 65%[3]. - The company's Q1 2024 net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between CNY 292.2 million and CNY 320.5 million, an increase of approximately CNY 103.65 million to CNY 131.95 million, representing a year-on-year growth of about 55% to 70%[3]. - In the same period last year, the net profit attributable to shareholders was CNY 172.93 million, and the net profit after deducting non-recurring gains and losses was CNY 188.55 million[5]. Factors Contributing to Profit Growth - The significant increase in net profit is attributed to the continuous introduction and gradual increase in sales of new products, initial success in market expansion, and enhanced customer loyalty[6]. - The company has optimized lean management and improved technical transformation capabilities, further enhancing cost control and overall strength[6]. - The company has made adjustments to its sales team and organizational structure, extending market management efforts and actively exploring emerging markets[6]. Earnings Forecast Reliability - There are no major uncertainties affecting the accuracy of this earnings forecast[7]. - The earnings forecast data is preliminary and the specific financial data will be disclosed in the official Q1 2024 report[7].

Financial Performance - In 2023, the company achieved total revenue of 830,871.98 million yuan, a year-on-year increase of 0.52%[3] - The net profit attributable to shareholders was 82,621.68 million yuan, representing a decline of 29.25% compared to the previous year[3] - The net profit excluding non-recurring gains and losses was 89,846.90 million yuan, down 22.08% year-on-year[3] - The basic earnings per share decreased by 29.63% to 0.57 yuan[3] - The weighted average return on net assets fell by 5.96 percentage points to 10.59%[3] Assets and Equity - Total assets at the end of the reporting period were 1,859,825.20 million yuan, an increase of 2.46% from the beginning of the period[3] - Shareholders' equity attributable to the company increased by 6.92% to 806,882.19 million yuan[3] Business Challenges - The company faced challenges in the raw material drug business due to intensified competition and price declines[5] - The company reported a significant decrease in non-recurring gains and losses, primarily due to fair value losses from invested entities[5] Financial Reporting - The company warns that the financial data presented are preliminary and may differ from the final audited report[6]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2023-138 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的他达拉非片的《药品注册证书》，现将 相关情况公告如下： 一、药品的基本情况 药品名称：他达拉非片 截止目前，公司在他达拉非片国内研发项目上已投入研发费用约人民币 802 万元。 三、对公司的影响 剂型：片剂 规格：20mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 申请人：浙江华海药业股份有限公司 药品批准文号：国药准字 H20234562 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二 ...

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2023-137 号 二、 回购的进展情况 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定， 回购期间公司应在每个月的前 3 个交易日公告截至上月末的回购进展情况。现将公司 回购股份进展情况公告如下： 2023 年 11 月 16 日，公司通过集中竞价交易方式首次回购股份 606,200 股，已回 购股份占公司总股本的比例为 0.04%，成交的最高价格为 15.67 元/股，成交的最低价 格为 15.55 元/股，已支付的总金额为 9,470,206.83 元（不含交易费用）。 浙江华海药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购方案的实施情况：截至 2023 年 11 月 30 日，公司已累计回购公司股份 1,346,200 股，占公司总股本的 0.0908%，成交的最高价格为 15.79 元/股，最低价 ...